Atheris Knowledge Hub

The Fast Tack Paradox: Why Biotech Companies Are Leaving Millions on the Table and Patients Waiting

Biotech companies systematically ignore FDA Fast Track pathway despite proven benefits, leaving millions in shareholder value and critical patient treatments unnecessarily delayed.